Log in

APTA Aptamer Group Plc LSE · United Kingdom

Aptamer Group Plc (APTA) news

Aptamer Group Plc is a public biotech or pharmaceutical company listed on LSE under the ticker APTA, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Aptamer Group Plc news

We have not published a story on Aptamer Group Plc yet. When there is news, it will appear here.

Questions about Aptamer Group Plc

What is the ticker symbol of Aptamer Group Plc?

Aptamer Group Plc trades under the ticker APTA on LSE.

Where is Aptamer Group Plc listed?

Aptamer Group Plc is listed on LSE.

Which country or territory is Aptamer Group Plc listed under?

Our directory records Aptamer Group Plc under United Kingdom.

What does Aptamer Group Plc do?

Our directory classifies Aptamer Group Plc as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Aptamer Group Plc?

The ISIN recorded for Aptamer Group Plc is GB00BNRRP542.

Does aibio.space cover Aptamer Group Plc?

aibio.space lists Aptamer Group Plc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Aptamer Group Plc?

Companies in our directory listed in the same country and business area as Aptamer Group Plc: Scancell Holdings Plc, COMPASS Pathways Plc, Oxford BioMedica, Thalia Therapeutics, Mereo BioPharma Group, Vidac Pharma Holding Plc.

Investor discussion: Aptamer Group Plc

Members talk about Aptamer Group Plc (APTA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open LSE:APTA on TradingView.

Listing details

Aptamer Group Plc is a public biotech or pharmaceutical company listed on LSE under the ticker APTA, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Aptamer Group Plc
Ticker
APTA
Listing
LSE
Country or territory
United Kingdom
Business scope
Biotechnology
ISIN
GB00BNRRP542
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.